What is Cannaray?
Cannaray distinguishes itself as a premier UK-based medical cannabis and CBD enterprise, uniquely supported by a Scientific Advisory Board composed of key opinion leaders. The organization focuses on five critical therapeutic areas: Multiple Sclerosis, chemotherapy-induced nausea and vomiting, epilepsy, chronic pain, and Tourette syndrome. By integrating rigorous scientific oversight with commercial operations, Cannaray maintains a competitive advantage in a sector where regulatory compliance and clinical efficacy are paramount. The company's business model centers on the intersection of high-quality product distribution and evidence-based medical advocacy, positioning it as a cornerstone of the evolving UK healthcare landscape.
The firm's strategic focus on specialized medical applications allows it to navigate the complexities of the UK regulatory environment effectively. By prioritizing clinical validation, Cannaray is not merely a consumer-facing CBD brand but a sophisticated medical entity aiming to standardize treatment protocols for patients with complex, chronic conditions.
How much funding has Cannaray raised?
Cannaray has raised a total of $9.6M across 1 funding round:
Series A
$9.6M
Series A (2019): $9.6M, investors not publicly disclosed
Key Investors in Cannaray
Undisclosed Investor
An undisclosed institutional partner providing strategic capital to support the growth and clinical development of Cannaray.
What's next for Cannaray?
With the successful acquisition of this major strategic investment, Cannaray is entering a critical phase of operational scaling. The company is expected to utilize these resources to deepen its research initiatives and potentially broaden its therapeutic portfolio. As the regulatory framework for medical cannabis continues to mature in the United Kingdom, Cannaray is well-positioned to capitalize on increased clinical adoption and market demand. Future growth will likely hinge on the company's ability to translate its scientific advisory insights into scalable, patient-centric solutions that meet the stringent requirements of the National Health Service and private healthcare providers alike. The focus remains on long-term value creation through clinical excellence and strategic market penetration.
See full Cannaray company page
